The hsFLJ22386 gene, an unknown gene, was located on chromosome 16p13.3. Its protein product contains 287 amino acids with the molecular weight of 32.2 kDa approximately. Predicted by bioinformatics, hsFLJ22386 might be a protein containing a leucine zipper domain. Based on the results of reverse transcriptase polymerase chain reaction, it revealed that FLJ22386 was expressed in several nervous system tissues and several organ tissues (liver, spleen, small intestine and kidney). In human cancer cell lines, the RT-PCR results showed that FLJ22386 was expressed in brain tumor cell lines (T98G, U87MG, U251, GBM8401), nasopharyngeal epithelial cell line (NNE-3)and carcinoma cell lines (NPCTW01, NPCTW04), hepatoma cell lines (J5, Hep3B, SK-Hep-1) and lymphoma cell lines (RPMI, P3HR1, Raji, U937). Human FLJ22386 coding sequence was inserted into pEGFP-C2 plasmid, and the tag-fused gene was transfected into NIH3T3 cells to see if it has the ability to promote cell proliferation. To further investigate the protein level expression and biological functions of the gene, glutathione S-transferase-hsFLJ22386 fusion protein was expressed and used to generate anti-FLJ22386 polyclonal antibody. According to the results of RT-PCR and anchorage dependent growth assay, it is presumed that FLJ22386 may play a role in cell proliferation.